Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Zelquistinel Under Fasted and Fed Conditions in Healthy Adults
NCT07099989Phase 1Active, not recruiting
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zelquistinel in major depressive disorder (MDD) (4 cohorts). Primary endpoints: Maximum Concentration, Area Under the Curve and 2 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
zelquistinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07099989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099989.